# SAABR (NCT04262154)

> Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: atezolizumab plus abiraterone plus prednisone; atezolizumab plus enzalutamide
- Indication: newly diagnosed hormone-sensitive metastatic prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04262154
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Metastatic Prostate Cancer
- Interventions: Atezolizumab; Abiraterone; Prednisone; GnRH analog; Stereotactic Body Radiotherapy (SBRT); Enzalutamide; Follow up
- Enrollment: 28
- Primary outcome: Failure-free Rate at 2 Years

## Indexed commentary on SAABR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=saabr-nct04262154